{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:36:33Z","timestamp":1793262993935,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sickle cell disease (SCD) is an autosomal recessive disease in which homozygosity for a single point mutation in the gene encoding the \u03b2-globin chain produces hemoglobin S molecules that polymerize within the erythrocyte during deoxygenation; the result is sustained hemolytic anemia and vaso-occlusive events. As patients live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive episodes leads to progressive end-organ complications. This scenario culminates in the development of 1 or more major cardiovascular complications of SCD for which there are no approved or consensus therapies. These complications include elevated pulmonary artery systolic pressure, pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, sudden death, and chronic kidney disease with associated proteinuria, microalbuminuria, and hemoglobinuria. In patients with advancing age, cardiopulmonary organ dysfunction and chronic kidney injury have significant effects on morbidity and premature mortality. Over the last 15 years, a number of tests have been validated in multiple replicate cohort studies that identify patients with SCD at the highest risk of experiencing pulmonary and systemic vasculopathy and death, providing for screening strategies tied to targeted, more aggressive diagnostic and therapeutic interventions.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.423","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Cardiovascular complications in patients with sickle cell disease"],"prefix":"10.1182","volume":"2017","author":[{"given":"Mark T.","family":"Gladwin","sequence":"first","affiliation":[{"name":"Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA; Heart and Vascular Institute, UPMC, Pittsburgh, PA; and Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703270078900_B1","first-page":"2565","article-title":"Cardiovascular complications and risk of death in sickle-cell disease","author":"Gladwin","year":"2016"},{"key":"2019111703270078900_B2","first-page":"115","article-title":"Pulmonary arterial hypertension: the clinical syndrome","author":"Lai","year":"2014"},{"key":"2019111703270078900_B3","first-page":"D42","author":"Hoeper","year":"2013"},{"key":"2019111703270078900_B4","first-page":"727","author":"Klings","year":"2014"},{"key":"2019111703270078900_B5","first-page":"840","author":"Mehari","year":"2013"},{"key":"2019111703270078900_B6","first-page":"1254","article-title":"Mortality in adults with sickle cell disease and pulmonary hypertension","author":"Mehari","year":"2012"},{"issue":"9","key":"2019111703270078900_B7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111703270078900_B8","first-page":"717","article-title":"SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction","author":"Lai","year":"2016"},{"key":"2019111703270078900_B9","first-page":"285","author":"Dixon","year":"2016"},{"key":"2019111703270078900_B10","first-page":"2010","author":"Naik","year":"2014"},{"key":"2019111703270078900_B11","first-page":"760","author":"Novelli","year":"2012"},{"key":"2019111703270078900_B12","first-page":"1272","article-title":"Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension","author":"Anthi","year":"2007"},{"key":"2019111703270078900_B13","first-page":"319","author":"Ghofrani","year":"2013"},{"key":"2019111703270078900_B14","first-page":"1690","article-title":"Successful pulmonary thromboendarterectomy in two patients with sickle cell disease","author":"Yung","year":"1998"},{"key":"2019111703270078900_B15","first-page":"1257","article-title":"Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival","author":"Castro","year":"2003"},{"key":"2019111703270078900_B16","first-page":"44","author":"Parent","year":"2011"},{"key":"2019111703270078900_B17","first-page":"112","article-title":"Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease","author":"Fonseca","year":"2012"},{"key":"2019111703270078900_B18","first-page":"750","author":"Kato","year":"2017"},{"key":"2019111703270078900_B19","first-page":"2254","author":"Gladwin","year":"2008"},{"key":"2019111703270078900_B20","first-page":"19","article-title":"Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes","author":"De Castro","year":"2008"},{"issue":"1","key":"2019111703270078900_B21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2006.06110.x","article-title":"Pulmonary hypertension in patients with sickle cell disease: a longitudinal study","volume":"134","author":"Ataga","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111703270078900_B22","first-page":"1452","author":"Sachdev","year":"2011"},{"key":"2019111703270078900_B23","first-page":"225","article-title":"An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease","author":"Lorch","year":"2011"},{"key":"2019111703270078900_B24","first-page":"416","article-title":"Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review","author":"Caughey","year":"2015"},{"key":"2019111703270078900_B25","first-page":"1158","article-title":"Haematological determinants of cardiac involvement in adults with sickle cell disease","author":"Damy","year":"2016"},{"key":"2019111703270078900_B26","first-page":"472","author":"Sachdev","year":"2007"},{"key":"2019111703270078900_B27","first-page":"E5182","article-title":"Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology","author":"Bakeer","year":"2016"},{"key":"2019111703270078900_B28","first-page":"243","article-title":"Cardiomyopathy with restrictive physiology in sickle cell disease","author":"Niss","year":"2016"},{"key":"2019111703270078900_B29","first-page":"205","article-title":"Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia","author":"Niss","year":"2017"},{"key":"2019111703270078900_B30","first-page":"310","author":"Machado","year":"2006"},{"key":"2019111703270078900_B31","first-page":"e99489","author":"Gladwin","year":"2014"},{"key":"2019111703270078900_B32","first-page":"729","article-title":"Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia","author":"Saraf","year":"2014"},{"key":"2019111703270078900_B33","first-page":"2228","author":"Guasch","year":"2006"},{"key":"2019111703270078900_B34","first-page":"363","author":"Powars","year":"2005"},{"key":"2019111703270078900_B35","first-page":"1639","article-title":"Mortality in sickle cell disease","author":"Platt","year":"1994"},{"key":"2019111703270078900_B36","first-page":"1371","article-title":"New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy","author":"da Silva","year":"2011"},{"key":"2019111703270078900_B37","first-page":"238","author":"Klings","year":"2014"},{"key":"2019111703270078900_B38","first-page":"646","article-title":"Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease","author":"Mekontso Dessap","year":"2008"},{"key":"2019111703270078900_B39","first-page":"703","article-title":"Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease","author":"Detterich","year":"2015"},{"key":"2019111703270078900_B40","first-page":"707","article-title":"Regular automated red cell exchange transfusion in the management of pulmonary hypertension in sickle cell disease","author":"Tsitsikas","year":"2014"},{"key":"2019111703270078900_B41","first-page":"e163","author":"Weir","year":"2017"},{"key":"2019111703270078900_B42","first-page":"737","article-title":"Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease","author":"Minniti","year":"2009"},{"key":"2019111703270078900_B43","first-page":"445","article-title":"Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension","author":"Machado","year":"2005"},{"key":"2019111703270078900_B44","first-page":"855","article-title":"walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","author":"Machado","year":"2011"},{"key":"2019111703270078900_B45","first-page":"641","article-title":"Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation","author":"Pittman","year":"2017"},{"key":"2019111703270078900_B46","first-page":"33","article-title":"Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia","author":"Gordeuk","year":"2011"},{"key":"2019111703270078900_B47","first-page":"340","article-title":"Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation","author":"Minniti","year":"2009"},{"key":"2019111703270078900_B48","first-page":"464","article-title":"Walk\u2013PHASST Investigators and Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe","author":"Nouraie","year":"2013"},{"key":"2019111703270078900_B49","first-page":"2877","article-title":"Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature","author":"Kelly","year":"2016"},{"key":"2019111703270078900_B50","first-page":"237","article-title":"Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption","author":"Hassell","year":"2014"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/423\/1250506\/hem00059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/423\/1250506\/hem00059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:27:06Z","timestamp":1573979226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/423\/21106\/Cardiovascular-complications-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.423","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}